| Authors: |
Li X; Halozyme Therapeutics, Inc., San Diego, California., Shepard HM; Halozyme Therapeutics, Inc., San Diego, California., Cowell JA; Halozyme Therapeutics, Inc., San Diego, California., Zhao C; Halozyme Therapeutics, Inc., San Diego, California., Osgood RJ; Halozyme Therapeutics, Inc., San Diego, California., Rosengren S; Halozyme Therapeutics, Inc., San Diego, California., Blouw B; Halozyme Therapeutics, Inc., San Diego, California., Garrovillo SA; Halozyme Therapeutics, Inc., San Diego, California., Pagel MD; Department of Cancer Systems Imaging, University of Texas, MD Anderson Cancer Center, Houston, Texas., Whatcott CJ; Clinical Translational Research Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona., Han H; Clinical Translational Research Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona., Von Hoff DD; Clinical Translational Research Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona., Taverna DM; Halozyme Therapeutics, Inc., San Diego, California., LaBarre MJ; Halozyme Therapeutics, Inc., San Diego, California., Maneval DC; Halozyme Therapeutics, Inc., San Diego, California., Thompson CB; Halozyme Therapeutics, Inc., San Diego, California. cthompson@halozyme.com. |